ArticlePLoS neglected tropical diseases2017
SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies.
Article in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04495569 (A Phase 1 Single Center, Parallel, Open Label Bridging Study to Evaluate on the Safety, Pharmacokinetic, Pharmacodynamics and Anti-drug Antibodies), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1 Single Center, Parallel, Open Label Bridging Study to Evaluate on the Safety, Pharmacokinetic, Pharmacodynamics and Anti-drug Antibodies (ADA) of a Single Intramuscular Doses of SYN023 in Healthy Adult Subjects
Who cites it
30 citing papers in PubMed, 55 citations in OpenAlex.
- Passive Immunization Hesitancy Among Rabies-Exposed Individuals in China: A Multicenter Cross-Sectional Study.Tropical medicine and infectious disease · 2026Article
- mRNA-Encoded Antibodies: An Emerging Paradigm in Antiviral Protection.Biomolecules · 2026Review
- A novel double-mAb sandwich ELISA utilizing broad-spectrum neutralizing antibodies as anFrontiers in immunology · 2026Article
- A Fully Human Derived Monoclonal Antibody Provides Potent Pre- and Postexposure Protection Against Rabies Virus.Transboundary and emerging diseases · 2026Article
- A SynB1-conjugated antibody cocktail crosses the blood-brain barrier to produce a therapeutic effect on rabies.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Research trends in anti-rabies virus monoclonal antibody: A bibliometric analysis.Human vaccines & immunotherapeutics · 2025Article
- Structural basis for broad neutralization of rabies virus by an antibody cocktail SYN023.Emerging microbes & infections · 2025Article
- The Clinical Advantages of Anti-Rabies Monoclonal Antibodies in Post-Exposure Prophylaxis - Worldwide, 2016-2025.China CDC weekly · 2025Article
- Efficacy Evaluation of Virus Clearance of SYN023 in A Murine Rabies Model - China, 2025.China CDC weekly · 2025Article
- Innovative approaches to vector control: integrating genomic, biological, and chemical strategies.Annals of medicine and surgery (2012) · 2025Review
- Circulating Antibody's Role During Post-Exposure Prophylaxis, and Beyond for Rabies: A Review.Vaccines · 2025Review
- Deep mutational scanning of rabies glycoprotein defines mutational constraint and antibody-escape mutations.Cell host & microbe · 2025Article
- Safety and tolerability of a novel monoclonal antibody cocktail for rabies post-exposure prophylaxis.NPJ vaccines · 2025Article
- Development of Human Monoclonal Antibodies With Broad Reactivity for Rabies Postexposure Prophylaxis.Journal of medical virology · 2024Article
- Development of novel canine phage display-derived neutralizing monoclonal antibody fragments against rabies virus from immunized dogs.Scientific reports · 2024Article
- Antiviral mechanisms of two broad-spectrum monoclonal antibodies for rabies prophylaxis and therapy.Frontiers in immunology · 2023Article
- Pseudotyped Viruses for Lyssavirus.Advances in experimental medicine and biology · 2023Article
- Advances in the progress of monoclonal antibodies for rabies.Human vaccines & immunotherapeutics · 2022Review
- Research progress on neutralizing epitopes and antibodies for the Rabies virus.Infectious medicine · 2022Review
- Characterization of Single-Chain Fv Fragments of Neutralizing Antibodies to Rabies Virus Glycoprotein.Viruses · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rabies is a neglected zoonotic disease that is preventable in humans by appropriate post-exposure prophylaxis (PEP). However, current PEP relies on polyclonal immune globulin products purified from pooled human (HRIG) or equine (ERIG) plasma that are either in chronic shortage or in association with safety concerns. Here, we present the development of an antibody cocktail, SYN023, made of two novel monoclonal antibodies (MAb) CTB011 and CTB012 that could serve as safer and more cost-effective alternatives to the current RIG products. Both CTB011 and CTB012 are humanized MAbs that bind to non-overlapping epitopes on the rabies virus (RABV) glycoprotein (G) with sub-nanomolar affinities. Sequence analysis revealed that many of the critical residues in binding are highly conserved across different species of lyssaviruses. When combined at a 1:1 ratio, CTB011/CTB012 exhibited neutralization capabilities equivalent or superior to HRIG against 10 North American street RABV isolates in vitro and 15 prevalent Chinese RABV strains in animal models. Finally, SYN023, at a dosage of 0.03 mg/kg, was able to offer the same degree of protection as standard HRIG administration (20 IU/kg) in Syrian hamsters challenged with a highly virulent bat (Tadarida brasiliensis) RABV variant. Taken together, the high-potency and broad-spectrum neutralization demonstrated by SYN023 make it an effective candidate for human rabies PEP consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.